Skip to the answer

Irinotecan Uses, Dosage, Side Effects and Interactions

Brand name
Camptosar

Camptosar was the first irinotecan product the FDA approved, in June 1996. An FDA-approved generic with the same active ingredient is listed.

Irinotecan is an intravenous chemotherapy (a topoisomerase inhibitor) used for metastatic colon or rectum cancer, and, as the liposomal product Onivyde, for metastatic pancreatic cancer.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 19, 2026 Where our facts come from

Quick links

Ask Anything About IrinotecanType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Irinotecan in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Irinotecan (Camptosar) is an IV chemotherapy that blocks topoisomerase I, an enzyme cancer cells need to copy their DNA, and since the mid-1990s it has been a standard partner to 5-FU and leucovorin for colon or rectal cancer that has spread (FDA-approved generics are listed), while a separate fat-coated (liposomal) form, Onivyde, treats pancreatic cancer that has spread. It is a demanding treatment, and diarrhea, nausea, tiredness and hair loss are what most people notice. The boxed warning is for severe diarrhea and dangerously low white blood cells, so report fever or any diarrhea to your care team right away.

Key Takeaways From the HelloPharmacist Team

  • Expect a 90-minute IV infusion at the clinic, given weekly, every two weeks or every three weeks depending on your regimen.
  • Keep loperamide at home and use it exactly as your care team directs for diarrhea starting a day or more after treatment.
  • Tell the nurse at once if sweating, cramping, watery eyes, drooling or a slow heartbeat start during or soon after the infusion.
  • Keep every lab appointment, because your blood counts are checked regularly and doses are held if white cells drop too low.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Irinotecan.

Onivyde can cause severe, life-threatening low white blood cell counts and severe diarrhea.

Neutropenia (low infection-fighting white cells) has led to fatal infections and fevers. Your blood counts are checked regularly, and treatment is held if counts drop too low or a neutropenic fever develops. Severe diarrhea can also occur. Treatment is held for moderate to severe diarrhea, and Onivyde must not be given if you have a bowel obstruction. Loperamide is used for late diarrhea and atropine, if safe for you, for early diarrhea. Report fever or any diarrhea right away.

Read the full warning on DailyMed →

Irinotecan by the Numbers

Strengths
3
in one form
Makers and packagers
13
Earliest FDA record
1996
Rank by Medicaid prescriptions
#780 of 1,666 drugs
More prescriptions than 53% of the 1,666 drugs we measure
25,359 prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Irinotecan

What It’s Used For

Irinotecan is a chemotherapy given into a vein for certain advanced cancers.

  • Irinotecan hydrochloride injection (including Camptosar): first-line treatment of metastatic colon or rectum cancer with 5-FU and leucovorin.
  • Irinotecan hydrochloride injection (including Camptosar): metastatic colon or rectum cancer that has returned or progressed after fluorouracil-based therapy.
  • Onivyde: first-line metastatic pancreatic adenocarcinoma in adults, with oxaliplatin, fluorouracil and leucovorin.
  • Onivyde: metastatic pancreatic adenocarcinoma after progression on gemcitabine-based therapy, with fluorouracil and leucovorin. It is not approved as a single agent.

How It Works

Irinotecan is a camptothecin that targets topoisomerase I, an enzyme that relieves tension in DNA as cells copy it. Irinotecan and its active form, SN-38, trap the enzyme on the DNA so the breaks cannot be sealed.

This causes double-strand DNA damage while cells are dividing. Cells cannot repair that damage efficiently, so they die.

Drug Class

Drug Class

  • Topoisomerase Inhibitor
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Topoisomerase Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Topoisomerase Inhibitors

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Irinotecan in the FDA’s index.

From our Patient Information GuideIrinotecan is a camptothecin that targets topoisomerase I, an enzyme that relieves tension in DNA as cells copy it. Irinotecan and its active form, SN-38, trap the enzyme on the DNA so the breaks cannot be sealed. Read How Irinotecan Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Irinotecan in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Topoisomerase 1 (TOP1) inhibitors

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Irinotecan is given only by IV infusion in a clinic or hospital, generally over about 90 minutes. Schedules vary by product and regimen, and may be weekly, every two weeks or every three weeks.

  • Camptosar and other irinotecan injections are given before leucovorin and 5-FU in combination regimens.
  • Onivyde is given before oxaliplatin, fluorouracil and leucovorin, after premedication with a corticosteroid and anti-nausea drug.
  • Onivyde cannot be swapped for other irinotecan products.

Follow your prescriber's plan and contact them if you miss a visit.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Irinotecan Injection

Colon or rectal cancer that has spread
Adults getting irinotecan with 5-FU and leucovorin, regimen 1 Usual dose 125 mg/m2 on days 1, 8, 15, 22 of a 6-week cycle
  • 125 mg/m2 intravenous infusion over 90 minutes, days 1, 8, 15, 22, with LV 20 mg/m2 intravenous bolus and 5-FU 500 mg/m2 intravenous bolus on days 1, 8, 15, 22
  • Next cycle begins on day 43

Good to know

Dose Level -1 is 125 to 100 mg/m2 (LV 20, 5-FU 400); Dose Level -2 is 75 mg/m2 (LV 20, 5-FU 300)

Adults getting irinotecan with 5-FU and leucovorin, regimen 2 Usual dose 180 mg/m2 on days 1, 15, 29 of a 6-week cycle
  • 180 mg/m2 intravenous infusion over 90 minutes, days 1, 15, 29, with LV 200 mg/m2 intravenous infusion over 2 hours, 5-FU 400 mg/m2 intravenous bolus and 5-FU 600 mg/m2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30
  • Next cycle begins on day 43

Good to know

Dose Level -1 is 150 mg/m2 (LV 200, 5-FU 400 bolus changed to 320, infusion 480); Dose Level -2 is 120 mg/m2 (LV 200, 5-FU 240 bolus, 360 infusion)

Adults getting irinotecan alone, weekly Usual dose 125 mg/m2 on days 1, 8, 15, 22 Highest dose 150 mg/m2
  • 125 mg/m2 intravenous infusion over 90 minutes, days 1, 8, 15, 22 then 2-week rest

Good to know

Dose Level -1 is 100 mg/m2; Dose Level -2 is 75 mg/m2

Adults getting irinotecan alone, every 3 weeks Usual dose 350 mg/m2 once every 3 weeks
  • 350 mg/m2 intravenous infusion over 90 minutes, once every 3 weeks

Good to know

Dose Level -1 is 300 mg/m2; Dose Level -2 is 250 mg/m2; may be adjusted as low as 200 mg/m2

See the Full Dosing Instructions on DailyMed →

Onivyde

Pancreatic cancer that has spread
Metastatic pancreatic adenocarcinoma, first-line, with oxaliplatin, fluorouracil and leucovorin Usual dose 50 mg/m2 every 2 weeks
  • 50 mg/m2 intravenous infusion over 90 minutes every 2 weeks, regardless of UGT1A1*28 genotype

Good to know

No recommended dose for serum bilirubin above the upper limit of normal; after adverse reactions resume at 40 mg/m2 (first), 32.5 mg/m2 (second), 25 mg/m2 (third); discontinue at fourth

Metastatic pancreatic adenocarcinoma after gemcitabine-based therapy, with fluorouracil and leucovorin Usual dose 70 mg/m2 every 2 weeks
  • 70 mg/m2 intravenous infusion over 90 minutes every 2 weeks

Good to know

After Grade 3 or 4 reactions resume at 50 mg/m2 (first), 43 mg/m2 (second); discontinue at third. No recommended dose for bilirubin above upper limit of normal

Adults known to be homozygous for UGT1A1*28 Starting dose 50 mg/m2 over 90 minutes Usual dose 70 mg/m2 every 2 weeks

Step by step

  1. Starting dose 50 mg/m2 intravenous infusion over 90 minutes
  2. Increase to 70 mg/m2 as tolerated in subsequent cycles

Good to know

After Grade 3 or 4 reactions without previous increase to 70 mg/m2 resume at 43 mg/m2 (first), 35 mg/m2 (second); discontinue at third

See the Full Dosing Instructions on DailyMed →

Side Effects

Common side effects seen in studies include:

Common side effects

  • Diarrhea
  • Nausea and vomiting
  • Abdominal pain or cramping
  • Low white blood cell counts (neutropenia)
  • Anemia (low red blood cells)
  • Weakness or tiredness
  • Loss of appetite and weight loss
  • Hair loss
  • Constipation
  • Low white blood cells, red blood cells or platelets

When to get medical help

  • Severe diarrhea, especially later diarrhea starting more than 24 hours after treatment, which can cause dehydration or infection
  • Fever or signs of infection, which can signal dangerously low white blood cells
  • Signs of a serious allergic reaction such as swelling, trouble breathing or a severe rash
  • New or worsening shortness of breath, cough or fever, which may signal lung problems
  • Severe vomiting or diarrhea with dehydration, since kidney problems can follow
  • Early symptoms during or soon after infusion such as sweating, flushing, drooling, watery eyes, cramping or a slow heartbeat

Warnings and Precautions

  • Severe diarrhea: early (during or soon after infusion) and late (after 24 hours). Late diarrhea can cause dehydration and infection. Begin loperamide at the first loose stool as directed.
  • Low white blood cells: can lead to serious or fatal infections. Higher risk with the UGT1A1*28 variant, elevated bilirubin, or past pelvic or abdominal radiation.
  • Allergic reactions: severe reactions can occur and treatment is stopped.
  • Lung problems: new cough, shortness of breath or fever need prompt evaluation.
  • Kidney problems: usually after dehydration from vomiting or diarrhea.
  • Pregnancy: can harm a baby.

Interactions

Some medicines change irinotecan levels in the body.

  • Strong CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampin, rifabutin): lower irinotecan exposure.
  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, voriconazole, ritonavir): raise exposure and risk.
  • UGT1A1 inhibitors (atazanavir, gemfibrozil, indinavir): may raise SN-38 levels.
  • Diuretics and laxatives: avoid during diarrhea.

Interactions Listed in the FDA-Approved Label

From the Irinotecan prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampin, rifabutin)
    What happensExposure to irinotecan or its active metabolite SN-38 is substantially reduced.
    What to doDo not administer unless there are no therapeutic alternatives; consider substituting non-enzyme inducing therapies at least 2 weeks before starting irinotecan.
  • Strong CYP3A4 or UGT1A1 inhibitors (ketoconazole, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole, atazanavir, gemfibrozil)
    What happensMay increase systemic exposure to irinotecan or SN-38.
    What to doDiscontinue strong CYP3A4 inhibitors at least 1 week before starting irinotecan; do not administer unless there are no therapeutic alternatives.
  • What happensIrinotecan disposition was not substantially altered; SN-38 Cmax and AUC0-24 were reduced by 14% and 8% when irinotecan was followed by 5-FU and LV.
    What to doThis sequence of administration was used in the combination trials and is recommended.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection. • Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with irinotecan hydrochloride injection. 7.1 5-Fluorouracil (5-FU) and Leucovorin (LV) In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. Although the C max and AUC 0-24 of SN-38,the active metabolite, were reduced (by 14% and 8%, respectively) when irinotecan was followed by 5-FU and LV administration compared with when irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended. Formal in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted. 7.2 Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St. John's wort. The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined. Consider substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan hydrochloride injection therapy. Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection unless there are no therapeutic alternatives. 7.3 Strong CYP3A4 or UGT1A1 Inhibitors Irinotecan and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively,.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use after a severe allergic reaction to irinotecan or Onivyde.
  • Do not use Onivyde with a bowel obstruction. Irinotecan treatment should wait until an obstruction resolves.
  • Pregnancy: use effective contraception during treatment and for 6 months after. Males should use condoms for 3 months after.
  • Do not breastfeed during treatment and for 7 days after.
  • Effectiveness in children has not been established.
  • Adults over 65 are monitored closely for diarrhea.
  • Use caution with kidney or liver impairment. It is not recommended on dialysis.
  • Tell your doctor about Gilbert's syndrome, lung disease, or past radiation to the pelvis or abdomen.

Overdose

Overdoses of about twice the recommended dose have been reported and may be fatal. The main effects are severe neutropenia and severe diarrhea. There is no known antidote, so care focuses on supportive treatment to prevent dehydration and treat infections.

Half-Life and How Your Body Processes It

After IV infusion, irinotecan levels fall with a half-life of about 6 to 12 hours, and SN-38 about 10 to 20 hours. The liver converts irinotecan to SN-38, then the UGT1A1 enzyme inactivates SN-38. People with reduced UGT1A1 activity have higher SN-38 levels. CYP3A4 also breaks down irinotecan. Part of the drug leaves in urine and bile.

Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from freezing. Protect from light.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Irinotecan: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Irinotecan — the kind of thing our pharmacy team would talk through with you at the counter.

What is irinotecan used for?

Irinotecan injection, including Camptosar, treats metastatic colon or rectum cancer, either first with 5-FU and leucovorin or after earlier fluorouracil-based treatment. Onivyde is a separate product used with other drugs for metastatic pancreatic cancer.

How is irinotecan given?

It is given through a vein, usually over about 90 minutes, by your healthcare team. The schedule depends on the product and your regimen. Your team may also give anti-nausea medicine and steroids beforehand with Onivyde.

What should I do if I get diarrhea on irinotecan?

Diarrhea can be serious. Keep loperamide on hand and start it at the first loose stool as your care team directs. Call right away if it is severe, lasts, or comes with fever, dizziness or dehydration. Avoid laxatives and diuretics.

What happens if I miss a dose of irinotecan?

Because it is given in a clinic, call your care team as soon as you know you will miss or have missed a visit. They will decide how to reschedule.

Can I take other medicines or herbal products with irinotecan?

Check first. St. John's wort and certain seizure medicines can lower irinotecan levels. Some antifungals, antibiotics and HIV medicines can raise them. Tell your care team about everything you take.

Is irinotecan safe during pregnancy or breastfeeding?

It can harm an unborn baby. Use effective contraception during treatment and for 6 months after, and men should use condoms for 3 months after. Do not breastfeed during treatment and for 7 days after the last dose.

Is irinotecan available over the counter?

No. Irinotecan is a prescription medicine: every irinotecan product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was irinotecan first available?

The earliest FDA record we hold for irinotecan is from 1996: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when irinotecan was first used.

Who makes irinotecan?

13 companies currently list irinotecan products in the FDA's NDC Directory, including Eugia US LLC, BluePoint Laboratories, Hikma Pharmaceuticals USA Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of irinotecan?

Irinotecan is the generic name. Its brand name is Camptosar. Generic versions are listed under the name irinotecan.

What is the generic name of Camptosar?

The generic name of Camptosar is irinotecan. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is irinotecan?

Irinotecan belongs to the drug class Topoisomerase Inhibitor, its established pharmacologic class on the FDA label.

Is there a generic version of irinotecan?

Yes. FDA-approved generic versions of irinotecan are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does irinotecan come in?

Irinotecan is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 40 mg/2 mL and 100 mg/5 mL. Injection (into a vein), amount in each mL: 4.3 mg/mL. A listing does not mean every pharmacy stocks every strength.

Is there a irinotecan shortage?

Irinotecan is not on the FDA's drug shortage list as of Nov 19, 2026, but a company has told the FDA it is discontinuing one version of it. See which products the notice covers

Where can I read the irinotecan prescribing information (package insert)?

The full FDA-approved prescribing information for irinotecan, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Ipsen Biopharmaceuticals, Inc.'s, revised Mar 3, 2025, and links to it on DailyMed.

Is irinotecan gluten free?

No irinotecan label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 28 irinotecan products from 13 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's irinotecan by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See irinotecan inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Irinotecan

Skip the scrolling. Ask in your own words and get an answer from Irinotecan’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Irinotecan’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Irinotecan on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Irinotecan Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Irinotecan Forms and Strengths (How It Comes)

Irinotecan comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Irinotecan inactive ingredients by manufacturer.

Injection

Into a vein
Brands Camptosar (the first brand, 1996)
How this form is used
What it may be used for
  • Camptosar is used for metastatic colon or rectum cancer, first-line with 5-FU and leucovorin or after earlier fluorouracil-based therapy
  • Onivyde is used with other drugs for metastatic pancreatic adenocarcinoma, and is not for use alone
  • Irinotecan hydrochloride injection is used for metastatic colon or rectum cancer
Important instructions
  • Camptosar is given as a 90-minute IV infusion, followed by leucovorin and 5-FU when used in combination
  • Onivyde is given as a 90-minute IV infusion, before oxaliplatin, fluorouracil and leucovorin
  • Onivyde must not be substituted for other irinotecan products
  • Onivyde is given after a corticosteroid and an anti-nausea medicine about 30 minutes beforehand
Available strengths 4 strengths
28 FDA-listed product records ⓘ

Irinotecan on the U.S. Market: Products, Makers and Brands

How Irinotecan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

13 companies list 28 Irinotecan product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1996. The one brand name in the directory today is Camptosar; the rest are generics.

1
Dose forms ⓘ
13
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
28
FDA-listed product records ⓘ
1996
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (11) · Unfinished powder, for suspension (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Eugia US LLC14%
BluePoint Laboratories11%
Hikma Pharmaceuticals USA Inc.11%
Pharmacia & Upjohn Company LLC11%
Qilu Pharmaceutical Co., Ltd.11%
Apotex Corp.7%
Other makers36%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Irinotecan Is Used (Medicaid Data)

How many Irinotecan prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

25,359
Medicaid prescriptions filled (Q1–Q4 2025)
$7.3M paid by Medicaid, before rebates

How commonly is Irinotecan prescribed? Of the 1,666 medications we measure, Irinotecan ranks #780 by Medicaid prescriptions — more than 53% of them.

Where Irinotecan ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Irinotecan product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 5 mL / 20 mg/mL injection is the most-dispensed Irinotecan product — about 63% of these Medicaid prescriptions.

5 ML irinotecan hydrochloride 20 MG/ML Injection Most dispensed

15,884 Medicaid prescriptions (Q1–Q4 2025) 63% of Irinotecan prescriptions shown $1.2M paid by Medicaid, before rebates ≈ $77 per prescription, before rebates

13 of 24 listed NDCs had Medicaid claims. RxNorm 1726324

2 ML irinotecan hydrochloride 20 MG/ML Injection

6,574 Medicaid prescriptions (Q1–Q4 2025) 26% of Irinotecan prescriptions shown $568,836 paid by Medicaid, before rebates ≈ $87 per prescription, before rebates

13 of 24 listed NDCs had Medicaid claims. RxNorm 1726319

10 ML irinotecan hydrochloride liposome 4.3 MG/ML Injection

1,221 Medicaid prescriptions (Q1–Q4 2025) 5% of Irinotecan prescriptions shown $5M paid by Medicaid, before rebates ≈ $4,129 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1719772

25 ML irinotecan hydrochloride 20 MG/ML Injection

890 Medicaid prescriptions (Q1–Q4 2025) 4% of Irinotecan prescriptions shown $361,345 paid by Medicaid, before rebates ≈ $406 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1726492

15 ML irinotecan hydrochloride 20 MG/ML Injection

790 Medicaid prescriptions (Q1–Q4 2025) 3% of Irinotecan prescriptions shown $72,248 paid by Medicaid, before rebates ≈ $91 per prescription, before rebates

3 of 6 listed NDCs had Medicaid claims. RxNorm 1726333

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 31 of the 56 listed Irinotecan NDCs had Medicaid claims.

Compare Irinotecan Products

A representative set of FDA-listed product records for Irinotecan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 28 of 28 products — FDA National Drug Code Directory. See every product, package size and price: browse all 28 Irinotecan NDCs →

Irinotecan Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Irinotecan recalls since July 2021.

✅No Irinotecan recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Irinotecan in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
1
Strengths
5
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Ingredient (IN) Irinotecan RxCUI 51499
  1. Dose form (SCDF) Injection RxCUI 1726318
    In current FDA listings

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Irinotecan Brand Names

Irinotecan has one brand name on record: Camptosar. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Camptosar the first brand, 1996

Who Makes Irinotecan: Manufacturers and Labelers

13 companies list Irinotecan products with the FDA. By number of product records, the largest are Eugia US LLC, BluePoint Laboratories, Hikma Pharmaceuticals USA Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Eugia US LLC 4 BluePoint Laboratories 3 Hikma Pharmaceuticals USA Inc. 3 Pharmacia & Upjohn Company LLC 3 Qilu Pharmaceutical Co., Ltd. 3 Apotex Corp. 2 Gland Pharma Limited 2 Northstar Rx LLC 2 Xiromed LLC 2 Actavis Pharma, Inc. 1 Fresenius Kabi USA, LLC 1 Hospira, Inc. 1 Ipsen Biopharmaceuticals, Inc. 1

Sources for This Irinotecan Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Mar 3, 2025, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Irinotecan.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 18 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
18
Finished products in the current FDA directory
28
Companies listing them (makers, repackagers, distributors)
13
FDA labeler codes behind them ⓘ
13
Linked representative label ⓘ
Ipsen Biopharmaceuticals, Inc.
Linked label effective
Mar 3, 2025
Composite sections available
25
Linked SPL Set ID
c8b58efa-1820-48a4-b70d-62918fc4abfc
Linked SPL Document ID
72b1786a-3437-4799-8214-f37b5be5607c
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Ipsen Biopharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →